Organogenesis Holdings Inc(ORGO) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.83 | Insider Own | 44.68% | Shs Outstand | 128.7M | Perf Week | -8.29% |
| Market Cap | 0.12B | Forward P/E | - | EPS next Y | 77.45% | Insider Trans | - | Shs Float | 71.2M | Perf Month | -33.66% |
| Enterprise Value | 0.28B | PEG | - | EPS next Q | -0.17 | Inst Own | 51.42% | Short Float | 21.08% | Perf Quarter | -63.03% |
| Income | -0.11B | P/S | 0.26 | EPS this Y | -575.08% | Inst Trans | 4.65% | Short Ratio | 18.72 | Perf Half Y | -60.86% |
| Sales | 0.46B | P/B | 0.81 | EPS next 5Y | - | ROA | -19.4% | Short Interest | 15.00M | Perf YTD | -81.94% |
| Book/sh | 1.15 | P/C | 2.57 | EPS past 3/5Y | 9.43% -0.14% | ROE | -25.92% | 52W High | -86.78% ($7.08) | Perf Year | -78.04% |
| Cash/sh | 0.36 | P/FCF | 5.78 | Sales past 3/5Y | 7.76% 10.77% | ROIC | -24.34% | 52W Low | 0.73% ($0.93) | Perf 3Y | -57.86% |
| Dividend Est. | - | EV/EBITDA | 34.02 | EPS Y/Y TTM | -613.22% | Gross Margin | 63.15% | Volatility(W/M) | 9.25% 6.55% | Perf 5Y | -91.42% |
| Dividend TTM | - | EV/Sales | 0.61 | Sales Y/Y TTM | 6.5% | Oper. Margin | -5.4% | ATR (14) | 0.08 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3 | EPS Q/Q | -702.49% | Profit Margin | -23.14% | RSI (14) | 22.27 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.52 | Sales Q/Q | -56.68% | SMA20 | -21.01% ($1.19) | Beta | 1.45 | Target Price | $2 |
| Payout | - | Debt/Eq | 0.23 | Earnings | 2026/11/5 | SMA50 | -34.69% ($1.44) | Rel Volume | 0.87 | Prev Close | $0.99 |
| Employees | 854 | LT Debt/Eq | 0.2 | EPS/Sales Surpr. | -103.91% -19.38% | SMA200 | -61.62% ($2.45) | Avg Volume(3M) | 0.80M | Price | $0.94 |
| IPO | 2017/1/5 | Option/Short | Yes/Yes | Trades | 2287 | Volume | 698,273 | Change | -5.82% |
🩹 This U.S. healthcare company develops, manufactures, and sells regenerative medicine products targeting the advanced wound care, surgical, and sports medicine markets. It operates a single business segment with a portfolio of skin substitute and soft-tissue regeneration solutions—including Apligraf and PuraPly—and has established a strong presence in the chronic wound care field, particularly in the treatment of diabetic foot ulcers.
Over the past 1 year, on the lower side
87% below its 1-year high.
Traded about as much as usual. That is 87% of its average volume.
Next earnings report: November 5
9 days to go.
ORGO has a sound balance sheet but weak earning power
Of every $100 in sales, $5.40 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -575.1% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $26. Peers typically go for $197. Compared with its own 4-year average, it is 385% pricier now.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -91.4%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
21.1% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #56 of 83 in the industry
Based on market cap of $120M.
DERM#53 Journey Medical Corp $140M PER - 
CRDL#54 Cardiol Therapeutics Inc $135M PER - 
OGI#55 Organigram Global Inc $132M PER 2.1 ORGO#56 Organogenesis Holdings Inc $120M PER - 
BGM#57 BGM Group Ltd $112M PER - 
FAQ
What kind of company is ORGO?
ORGO belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of ORGO?
The market cap of ORGO is approximately $120M, ranking 4,374 within its sector.
What is the 52-week high and low for ORGO?
ORGO has recorded a 52-week high of $7.08 and a low of $0.93.
